In addition, Lev has received notification from the European Medicines Agency (EMEA) that it is eligible to submit an application for Cinrzye for Community marketing authorization through the centralized European registration procedure.
Cinryze is manufactured in Europe by Sanquin using a nano-filtration purification process under a distribution and manufacturing services agreement with Lev. Under its agreement with Sanquin, Lev currently holds the exclusive rights to market and distribute Cinryze for the treatment of hereditary angioedema in North America.
Lev is presently in discussions with Sanquin to expand its authorized territory to include certain European countries. Lev intends to submit its application to the EMEA in the fourth quarter of 2008.